Ceftolozane-tazobactam in nosocomial pneumonia

ABSTRACT

Ceftolozane is a potent antimicrobial against Pseudomonas aeruginosa, including carbapenem-resistant andmultidrug-resistant strains, and is also active against Enterobacteriaceae. It MIC (minimal inhibitory concentration) andMPC (mutant preventive concentration) are close together,allowing to avoid the mutant selection window specificallyin the treatment of Pseudomonas aeruginosa infection. Themolecule is time-dependent and stable when reconstituted atroom temperature, facilitating safe and effective dosage optimization in frail and critically ill patients. It has been shown tobe non-inferior to meropenem in the treatment of nosocomial infection in the ASPECT-NP study but superior in post-hocstudies in the subgroup of patients with ventilator-associatedpneumonia, without the emergence of resistance during treatment. It is FDA approved at a dose of 3 g every 8 hours in thetreatment of nosocomial pneumonia (HABP/VABP) in adults. (AU)